|
CANX expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62414526272414E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
2.03040000001931E-06 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62725388719309E-12 |
| Stage1-vs-Stage2 |
3.265500E-02 |
| Stage1-vs-Stage3 |
2.943600E-02 |
| Stage1-vs-Stage4 |
2.291900E-02 |
| Stage2-vs-Stage3 |
9.234400E-04 |
| Stage2-vs-Stage4 |
5.974500E-04 |
| Stage3-vs-Stage4 |
5.765200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
3.65199999999843E-05 |
| Normal-vs-Asian |
2.02060590481778E-14 |
| Caucasian-vs-AfricanAmerican |
2.327600E-01 |
| Caucasian-vs-Asian |
6.752800E-01 |
| AfricanAmerican-vs-Asian |
1.904790E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-16 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
5.443200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
4.44089209850063E-16 |
| Normal-vs-Age(61-80Yrs) |
1.63569158218024E-12 |
| Normal-vs-Age(81-100Yrs) |
1.584400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.993600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.882400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.406200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.880600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.787400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.445200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.88310478321796E-11 |
| Classical-VS-Follicular |
1.98871999999017E-05 |
| Classical-VS-Other |
2.310200E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.62558855265615E-12 |
| Tall-VS-Other |
1.145240E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
2.068000E-02 |
| Follicular-VS-Normal |
3.91010000000414E-05 |
| Other-VS-Normal |
1.74893000000065E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.78765899253131E-12 |
| Normal-vs-N1 |
1.62458935193399E-12 |
| N0-vs-N1 |
2.15219999999405E-05 |
|
|
